Collegium Pharmaceutical, the Stoughton, Massachusetts seller of branded pain medicines and an acquired attention-deficit portfolio, still supplies the tapentadol painkillers it markets as Nucynta, and prescribers still write them. What the company has stopped collecting is the price. The franchise produced $35.2m of net revenue in the June quarter, down 24% from a year earlier, and that figure already includes $5.1m of profit share on the authorized generic versions, with the decline attributed to lower net pricing on those generics. Chief executive Vikram Karnani put a number on it for investors: the authorized generic nets Collegium roughly 10% to 15% of branded net price for the immediate-release product and 20% to 25% for extended release.

The acquired ADHD franchise was read as the engine that replaces this. "In the second quarter, we saw strong demand across our ADHD portfolio, highlighted by record-high JORNAY PM prescriptions and prescriber adoption, alongside 41% revenue growth," Karnani said in the results release of 6 August 2026. It is growing: Jornay PM delivered $46.1m, on prescriptions up 13.1%. The same morning the company cut full-year revenue guidance from $865-895m to $825-855m and adjusted earnings before interest, taxes, depreciation and amortization to $445-470m, and the shares fell about 13.5% before the open.

The list price nobody pays

A specialty-pharma dollar is the residue of a much larger billed number. For the six months to 30 June 2025, Collegium's filings show provisions on current-period sales of $241.8m for rebates and incentives, $101.4m for trade allowances and chargebacks and $34.6m for returns — $377.8m of deductions against roughly $366m of net product revenue booked in the period. List price is approximately double what the company keeps.

That gap is where the quarter was lost. Xtampza ER's $4.5m revenue decline came from lower volume and higher gross-to-net adjustments, partly offset by a higher gross price: the sticker went up, the realization went down. Group gross margin fell to 55.2% from 62.5% two quarters earlier, operating margin to 1.9% from 30.4% a year ago, and the quarter closed with a $15.1m net loss on $199.9m of revenue. Statute is pushing the same way — the Inflation Reduction Act's Manufacturer Discount Program obliges makers to fund 10% of Part D cost in the initial phase and 20% in the catastrophic phase, a larger drag on high-priced specialty products than the program it replaced.

The calendar ends in January; the loans do not

US exclusivity for Nucynta immediate-release runs to 3 January 2027, and Belbuca's agreed generic entry date under its Teva settlement is the same month. Xtampza ER's agreed date is September 2033. Against that, $572.8m of principal was outstanding under the term loan at 31 March 2026, alongside $241.5m of 2.875% convertible notes due 2029, with the term facility maturing in November 2028 or December 2030 depending on conditions.

The replacement portfolio is purchased, not discovered. Collegium paid about $650m in cash for the Azstarys business in May 2026 — roughly $350m of balance-sheet cash plus a $300m delayed draw — and it contributed $12.9m of revenue from 12 May to 30 June. Half-year amortization of acquired intangibles ran to $118.4m against a cash cost of making the drugs of $47.4m.

Two other meters on the same dollar

Supernus, the Rockville CNS specialist, is the control on the pricing thesis and fails it: revenue rose 32% to $219.1m, Qelbree net sales 15% to $89.2m on prescriptions up 17%, and guidance went up to $860-890m. Its shares fell 11.8% over three months because each one now converts into 1.5401 Indivior shares; the quote is Indivior's.

Pacira, which sells the non-opioid injectable Exparel, confirms the mechanism from the hospital side. Vials rose 4% and net sales only 3%, to $147.8m, the gap owed to vial mix and a third group-purchasing-organisation discount contract; gross margin slipped 4 points to 77.0%. Its patent fight is settled — Fresenius Kabi is licensed no earlier than a confidential 2030 date — so what moves Pacira's dollar is whether payers reimburse the drug outside the surgical bundle, and that improved in the quarter. It trades at 8.7x forward earnings and 10.4x trailing EV/EBITDA, with an 18.1% trailing free-cash-flow yield.

What the fall has already paid for

Collegium closed at $22.02 on 2 October, down 40.5% in three months and 35.8% in a year, in a declining trend since mid-August. Comparable branded small-caps went in both directions over the same stretch — Alkermes fell 23.5% and Axsome 26.6%, while Corcept rose 28.8% and Amphastar 29.5%, with the S&P 500 up 3.3% — so this is a verdict on Collegium.

The business explains the direction fully: four quarters of decelerating revenue, a 7-point gross-margin compression, a cut guide and a franchise whose price has been reset by its own licensee. What the business does not obviously explain is the level. At 2.46x trailing EV/EBITDA and a 46% trailing free-cash-flow yield, against 14.4x trailing earnings versus roughly 20-26x a year ago, the shares are priced for the cash to stop, while consensus revenue holds near $850m through 2028. One of those is wrong, and the test is whether Jornay PM and Azstarys hold their guided $190-200m and $65-75m while the pain franchise finishes going.

There is one more cost arriving at this market-cap band: the 100% tariff on certain patented pharmaceutical products took effect at the end of September and exempts the large manufacturers that signed most-favored-nation pricing agreements. Collegium's ADHD portfolio has until January to become the company.